Performance in 2014 positions Lundbeck well for 2015 and beyond


Valby, Copenhagen, 2015-02-05 07:54 CET (GLOBE NEWSWIRE) --  

HIGHLIGHTS

  • In 2014 core products like Abilify Maintena®, Brintellix®, NortheraTM and Selincro® have been introduced in 39 markets worldwide and the ambitious launch program will accelerate in 2015
     
  • Revenue from New Products increased 46% in local currency in 2014 and now constitutes 33% of total revenue
     
  • US revenue reached DKK 3,758 million, an increase of 43% in local currency, and constitutes 28% of Lundbeck’s revenue in 2014
     
  • Revenue in International Markets up 9% in local currency, largely driven by China, and constitutes more than 31% of Lundbeck’s revenue
     
  • Brintellix has in its first year achieved a branded market share of more than 14% in the US and in-market sales of approximately DKK 840 million. Brintellix was launched in eleven additional countries in 2014
     
  • Abilify Maintena is off to a good start in Canada and in Europe. In the US, Abilify Maintena seems to regain positive momentum. Additionally, the QUALIFY study has provided superiority data on quality-of-life
     
  • Selincro was recently launched in France, a key market, and has been very well received by physicians and patients
  • Brintellix has entered a pivotal program for treatment of adult patients with ADHD
     
  • Brexpiprazole data presented at ACNP support the regulatory package in two indications, schizophrenia and adjunctive therapy of major depression, submitted in the US
     
  • Based on the financial results, the Board of Directors proposes no dividend payout for 2014
     
  • Financial guidance for 2015 in constant exchange rates is DKK 13.2-13.7 billion in core revenue and around DKK 0 in core EBIT

In connection with the full year report, Lundbeck’s Chairman Håkan Björklund said: 

“We are moving through a challenging period of patent expirations to a period of product launches. 2014 has been a successful year for Lundbeck with 39 launches across the world. We will continue to launch new products and in 2015 we potentially have more than 50 launches scheduled. We stay the course and in 2015 I also look forward to making brexpiprazole available in the US”.

 

DKK million FY 2014 FY 2013 Growth
Core Revenue* 13,468 14,242 (5%)
Core EBIT* 1,228 2,282 (46%)
Core EPS* 3.21 8.02  
Core EBIT margin 9.1% 16.0%  
Reported Revenue 13,468 15,258 (12%)
Reported EBIT 99 1,599 (94%)
Reported EPS (0.78) 4.36  
Reported EBIT margin 0.7% 10.5%  

*For definition of the measures “Core Revenue”, “Core EBIT” and “Core EPS”, see page 14, and reconciliation to reported figures, see page 21-22


Attachments

Lundbeck FY2014 Results.pdf